- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07629973
A Study of the Determinants of Neurological Outcomes in Patients With Acute Respiratory Distress Syndrome (NEURDS)
Etude Des déterminants de l'évolution NEUrologique Des Patients Ayant présenté un Syndrome de Détresse Respiratoire aiguë
Acute respiratory distress syndrome (ARDS) is characterized by pathological pulmonary edema caused by direct or indirect damage to the alveolar-capillary membrane.
Its management relies on etiological treatment, invasive mechanical ventilation, and the use of sedatives and neuromuscular blockers, depending on the patient's condition.
Improvements in patient care have led to an improved prognosis. However, in-hospital mortality remains high (between 35% and 45%). Notably, morbidity among surviving patients is very high and is largely dominated by neuropsychological sequelae. Attention and executive function disorders, confusion, disorientation, or memory impairment are thus found in 70 to 100% of patients following ARDS. These disorders are still present in 46 to 80% of surviving patients one year after ARDS and in 20% of them five years later.
Although essential to treatment, mechanical ventilation carries a risk of significant complications. Beyond the risk of infection and complications related to sedation and neuromuscular blockade, the use of mechanical ventilation is associated with a risk of ventilator-induced lung injury (VILI).
The use of so-called protective ventilation reduces the risk of VILI and improves patient outcomes. However, analysis of relevant physiological parameters shows that the risk of VILI may still exist even when ventilator settings comply with recommendations and the concept of protective ventilation. Driving pressure (which represents Strain) is a good marker of VILI; it represents the distension of the lung with each breath relative to the initial lung volume. Values above 14 cmH₂O are associated with high mortality in patients with ARDS. Inspiratory transpulmonary pressure represents Stress-that is, the pressure that distends the alveoli at the end of inspiration-and is also associated with the risk of VILI. Finally, mechanical power represents the amount of energy delivered to the lung by the ventilator and has been validated as a marker of VILI. The advantage of mechanical power over the other indices described is that it incorporates all components that can lead to VILI.
Among the various sources of neurological damage during ARDS, inflammatory processes appear to play a major role. Numerous inflammatory mediators (TNF-α, IL-6, IL-8, IL-1β) are secreted during ARDS, and animal studies have demonstrated a link between inflammation and hippocampal damage. Furthermore, cerebral ischemic lesions, exacerbated by systemic inflammation and endothelial activation leading to coagulation activation with thrombus formation, may also contribute to the development of cognitive impairments.
In addition to the inflammatory processes associated with ARDS, mechanical ventilation itself may have a significant impact on neuroinflammatory damage. Recently, the term "ventilator-associated brain injury" (VABI) has been proposed to describe these secondary neurological lesions induced by mechanical ventilation. Studies in mouse and pig models have demonstrated a relationship between the dose and duration of VILI, apoptosis, neuroinflammation, and neuronal damage. An animal study in mice also showed an association between the duration of mechanical ventilation and the onset of cognitive impairments.
During brain injury, proteins and neurotransmitters are released and serve as biomarkers of brain damage. Elevated plasma levels of S100B protein indicate astrocyte damage caused by traumatic, anoxic-ischemic, or inflammatory mechanisms. It correlates with neurological prognosis following cardiac arrest, in ischemic or hemorrhagic strokes, in neurodegenerative diseases, and in patients with traumatic brain injury.
Clinical studies have shown a negative correlation between elevated S100B protein levels, the MoCA (Montreal Cognitive Assessment) score, and the MMSE (Mini-mental state evaluation ) in patients with OSA (Obstructive Sleep Apnea) or COPD (chronic obstructive pulmonary disease), respectively, indicating an association between this protein and cognitive impairment.
The investigators therefore hypothesize that mechanical ventilation associated with high mechanical power is linked to a significant risk of brain injury, reflected by elevated serum S100B protein levels and the presence of neurocognitive disorders long after ARDS.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: François Beloncle, Professor
- Numéro de téléphone: +33 2 41 35 38 15
- E-mail: Francois.Beloncle@chu-angers.fr
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Adult patient
- Patient admitted to the intensive care unit less than 48 hours ago
Patient diagnosed with mild, moderate or severe ARDS according to the Berlin classification based on the PaO₂/FiO₂ ratio, with a minimum PEEP set at 5 cmH₂O (16), of pulmonary aetiology:
- Mild ARDS: 200 < PaO₂/FiO₂ < 300 mmHg
- Moderate ARDS: 100 < PaO₂/FiO₂ < 200 mmHg
- Severe ARDS: PaO₂/FiO₂ < 100 mmHg
- Patients fitted with an oesophageal pressure measurement catheter (Nutrivent, Sidam, San Giacomo Roncole, Italy)
- Patients registered with or covered by a social security scheme
- Free and informed consent from the patient or a trusted relative (where the patient is unable to give consent).
Exclusion Criteria:
- Patients with a history of central nervous system disorders resulting in cognitive impairment
- Patients on ECMO
- Patients admitted for symptomatic central nervous system disorders
- Patients admitted for acute respiratory distress syndrome following cardiorespiratory arrest.
- Patients being treated for a psychiatric condition, chronic heavy drinkers, or those undergoing long-term treatment with benzodiazepines, antidepressants or antipsychotics.
- Pregnant, breastfeeding or labouring patients
- Individuals subject to a legal protection order
- Individuals receiving compulsory psychiatric care
- Individuals deprived of their liberty by judicial or administrative decision
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: cohort
collection of oesophageal pressure data, mechanical power calculation, MOCA score collection and blood sample collection for S100B protein dosage
|
collection of oesophageal pressure data, mechanical power calculation, MOCA score collection and blood sample collection for S100B protein dosage
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
association between the mechanical power between Day 1 and Day 3 (reflecting the risk of VILI)
Délai: at day 1, day 2 and day 3
|
mechanical power calculation
|
at day 1, day 2 and day 3
|
|
S-100B serum protein level between Day 1 (H0) and Day 3 (H72).
Délai: at day 1, day 2 and day 3
|
S-100B protein dosage
|
at day 1, day 2 and day 3
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
association between serum S100B protein concentrations from day 1 to day 3 and neurological outcome at 3 months and 12 months
Délai: at 3 and 12 months
|
Correlation coefficient between S-100B protein levels from Day 1 to Day 3 and the MOCA (Montreal Cognitive Assessment) score at 3 and 12 months (no neurocognitive impairment if MOCA ≥ 26/30, neurocognitive impairment if < 25/30).
|
at 3 and 12 months
|
|
association between other VILI markers (inspiratory transpulmonary pressure and driving pressure) and serum S100B protein concentrations from day 1 to day 3.
Délai: From day 1 to day 3
|
Correlation coefficient between inspiratory transpulmonary pressure and driving pressure, and serum S-100B levels between Day 1 and Day 3, whilst accounting for potential confounding factors in a multivariate model
|
From day 1 to day 3
|
|
association between these other VILI markers and neurological outcomes at 3 months and 12 months.
Délai: at 3 and 12 months
|
Correlation coefficient between mechanical power, inspiratory transpulmonary pressure and driving pressure (average of values measured between J1 and J3) and the MOCA score at 3 and 12 months, taking potential confounding factors into account in a multivariate model
|
at 3 and 12 months
|
|
association between the occurrence of delirium during a stay in the intensive care unit and neurological outcomes at 3 and 12 months.
Délai: at 3 and 12 months
|
The occurrence of neurocognitive impairment, defined as a MoCA score of <25/30 at the 3- and 12-month assessments, in patients who experienced delirium in the intensive care unit compared with those who did not.
|
at 3 and 12 months
|
|
prevalence of depression among patients who presented ARDS
Délai: at 3 months
|
occurrence of depressive symptoms defined as a Patient Health Questionnaire-9 (PHQ-9) score > 10/27
|
at 3 months
|
|
prevalence of post-traumatic stress (PCL-5 score) among patients who presented ARDS
Délai: at 3 months
|
occurrence of post-traumatic stress defined as a Post-Traumatic Stress Disorder Checklist dor DSM-5 (PCL-5) score > 33/80
|
at 3 months
|
|
prevalence of anxiety among patients who presented ARDS
Délai: at 3 months
|
anxiety disorders defined as a General Anxiety Disorder-2 (GAD-2) score > 3/6
|
at 3 months
|
|
quality of life state (Euro 5d 5l score) among patients who presented ARDS
Délai: at 3 months
|
deterioration in quality of life measured with EuroQol-5D-5L (max 5 points) :score analysed both continuously and categorically
|
at 3 months
|
|
prevalence of independence among patients who presented ARDS
Délai: at 3 months
|
occurence of a decline in functional independence defined as the loss of at least one instrumental activity compared with the level prior to hospitalisation with the Instrumental Activities of Daily Living (IADL) score (from 8 to 30 max)
|
at 3 months
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 49RC25_0292
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .